Immunological effect of co-trimoxazole on platelets

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Co-trimoxazole is an antimicrobial drug frequently used for leukemia treatment and prophylaxis.
• Platelet disorders can significantly impact patient outcomes, especially in immunocompromised individuals.

Observation:

• Three patients experienced adverse effects related to co-trimoxazole, including diminished survival of transfused platelets and thrombocytopenia.
• An indirect immunofluorescence assay was employed to investigate the mechanism behind these platelet issues.

Findings:

• Antibodies against donor platelets coated with co-trimoxazole were detected in all affected patients.
• These antibodies were specifically directed against the trimethoprim component of co-trimoxazole, not the sulphamethoxazole component.

Implications:

• The findings highlight a significant adverse effect of co-trimoxazole on platelet function and survival.
• This is particularly important given the drug's common use in leukemia patients, who are already at risk for hematological complications.
• Further research may be warranted to explore alternative antimicrobial strategies or monitoring protocols for patients on co-trimoxazole.